Keywords: Sanofi-Aventis, Avila, Licensing, Merck KGaA, Merck Serono, Cancer candidates, Oxford University, Research, India

Sanofi-Aventis in $800 million deal with Avila; links up with Merck KGaA and with Oxford University for cancer research

Article | 20 December 2010

Print This

In what was a busy few days for French drug major Sanofi-Aventis (Euronext: SAN) in its quest to develop new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in